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1. Introduction
Diabetic ketoacidosis (DKA) is considered a predominantly acute type 1 diabetic complica‐
tion, although it may occur in type 2 diabetes as well, particularly in patients who already
have a decreased insulin secretion capacity. Stress –induced burst in catecholamine and
ACTH secretion in acute myocardial infarction (AMI) promotes release of free fatty acids
and their hepatic and muscular tissue utilization. The impairment in insulin-mediated intra‐
cellular glucose influx owing to the absent or insufficient pancreatic insulin secretion is the
prerequisite for the occurrence of diabetic ketoacidosis.
The results of the analysis of acid – base disturbances from our previous study [26] per‐
formed in the intensive-care unit in diabetics and non-diabetics suffering acute myocardial
infarction are shown in Fig. 1.
Cardiovascular accidents have a marked place among the possible causes of diabetic ketoa‐
cidosis. Cardiovascular morbidity influences the severity and duration of diabetic ketoaci‐
dosis and limits the first and most important step in its treatment- the fluid resuscitation.
The resulting hyperosmolarity of body fluids precipitates a pro-thrombotic state, thus aggra‐
vating prognosis in patients with myocardial infarction. The clinical features of hyperglyce‐
mic/hyperosmolar state and diabetic ketoacidosis may overlap and are observed
simultaneously (overlap cases) [44].
© 2013 Jovanovic et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. Acid-base disturbances in diabetics and non-diabetics suffering acute myocardial infarction: Almost one-
third of diabetic patients with acute myocardial infarction had un-compensated metabolic acidosis defined as pH< 35,
HCO3- < 22mmol/L. Although acidosis was mild in most of the cases at least third of these patients had criteria for
true diabetic ketoacidosis (pH<30, HCO3- <15mmol/L). Additional 30% had a compensated metabolic acidosis with
normal pH and mild to moderately decreased bicarbonate level. The pH was normalized at a price of the increased
respiratory effort to lower the PaCO2 which may lead to respiratory muscle fatigue.
Additional risk factors for development of hyperosmolarity include the presence of conges‐
tive heart failure, impaired thirst, limited access to water (especially in patients with demen‐
tia or who are bed bound), older age, and poor kidney function. Table 1 depicts the
significant correlations of pH values and certain clinical and biochemical parameters in dia‐
betics suffering AMI.











Table 1. Significant (p<0.05 and less) correlations between serum pH and clinical and biochemical parameters in
diabetics suffering AMIAs expected, serum pH correlated with glycemic control, but also with clinical and biochemical
parameters that were related to tissue hypo-perfusion (incidence of heart failure and rhythm/conduction
disturbances, haemoglobin oxygen saturation, serum lactate) and to infarct size and stress-hormone release (e.g.
serum creatinine – kinase and plasma noradrenaline values)
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Hyperosmolar state and circulatory impairment with decreased oxygen tissue delivery may
stimulate lactate production. Although true lactic acidosis occurs rarely, the increased lac‐
tate load may further contribute to the degree of acidosis. In our study, bicarbonate levels
was lower (p<0.05) and base deficit were significantly (p<0.01) higher in patients with diabe‐
tes mellitus and acute myocardial infarction comparing to patients with acute myocardial
infarction only. Serum lactate was moderately high (Fig.2), but true lactic acidosis defined as
serum lactate > 5 mmol/l was registered only in one case with lethal outcome. Moreover, it
seems that rise in the serum lactate level between diabetics and non-diabetics with AMI was
not accounted for the differences in oxygen delivery, since hemoglobin saturation was much
the same in both groups. Therefore, it seems that DKA itself caused further tissue hypo-per‐
fusion and contributed to serum lactate rise. These findings are compatible with the results
of the recent study performed by Cox et al. [14]
Figure 2. Serum lactate in diabetics and non-diabetics suffering AMIThe lactate level in diabetic / AMI patients was
higher (4.143 +- 0.914 vs. 3.156 +- 1.12 mmol/L, p<0.01) comparing to patients with acute myocardial infarction only
Finally, the intensive care unit mortality reached 15% among DM/AMI patients comparing
to 5% in patients with AMI only.
The excess in-hospital mortality of diabetic patients results primarily from an increased inci‐
dence of congestive heart failure, severe coronary artery disease, decreased vasodilatory re‐
serve of epicardial artery resistance, abnormal metabolism of myocardial substrate, diffuse
nature of the atherosclerotic disease and hyper-coagulable state. Autonomic neuropathy
predisposes patients to ventricular arrhythmia [5]. Also, inhibition of myocardial protective
mechanisms against ischaemia / reperfusion injury may contribute to the increased mortali‐
ty rate [46, 58]. The similar mechanisms are operative in developing cerebrovascular injury
in diabetics [18].
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Figure 3. Haemoglobin saturation (SaO2) in diabetics and non-diabetics suffering AMI and in control groupAlthough
SaO2 was significantly depressed in all patients suffering AMI comparing to control group subjects, there was no sig‐
nificant difference between diabetics and non-diabetics with AMI.
Diabetic acidosis itself may be the precipitating event for the occurrence of serious arrhyth‐
mia, pulmonary edema or even acute myocardial infraction [22]. When acidosis is severe, i.e.
pH is less than 7.2 the H+ ions have a direct cardiac depressant action. They cause negative
inotropy, bradycardia, reduced cardiac output, peripheral vasodilatation and severe shock.
Sometimes, a bio-marker elevation is also noted, without further evidence of a true myocar‐
dial infarction [42].
Potassium deficit is one of the most important of electrolyte imbalances seen in DKA, as it
can lead to fatal arrhythmia, especially when the serum potassium level is < 3 mmol/L. On
the other hand iatrogenic or spontaneously occurring hyperkalemia may lead to ventricular
tachycardia or fibrillation, intra-ventricular conduction defects, sine wave, slow ventricular
escape rhythm or ventricular stand. Hyperkalemia can also induce a current of injury called
‘dialyzable current of injury’, which can cause ST-segment elevation and thus be mistaken
for acute infarction. [7, 6)].
Pseudo-infarction presents a unique danger for the clinician treating these critically ill pa‐
tients. While the mechanism of these and other temporary electrocardiographic changes in
diabetic ketoacidosis remains unclear, appreciation of their transient nature is essential if
misdiagnosis of myocardial infarction and possible inappropriate delay in intravenous fluid
administration are to be avoided [21]. However a true myocardial necrosis was also report‐
ed with the DKA as the precipitating factor [50], which further complicates the management
and the outcome of these patients.
A pulmonary edema in the absence of left ventricular failure has also been reported in DKA
and may be a variant of adult respiratory distress syndrome (ARDS). The aetiology may be
pulmonary vascular microangiopathy seen in diabetics. Vigorous fluid therapy can precipi‐
tate this condition.
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Since volume repletion must be done cautiously and gradually, its therapeutic reach in dia‐
betic ketoacidosis is limited. Intravenous insulin remains the keystone in treatment of dia‐
betics with AMI, yet their recovery from ketoacidosis may be prolonged.
Potassium levels must be monitored continuously and corrected as need occurs. If the potas‐
sium level is less than 3.3 mEq per L (3.3 mmol per L), potassium replacement should be
given immediately and insulin should be started only after the potassium level is above 3.3
mEq per L. Phosphate replacement is needed occasionally.
Bicarbonate therapy is not recommended unless pH falls to critically low levels (<7.0). Even
then, positive effects of bicarbonate therapy remain questionable.
Phosphate replacement is done only if the patient’s serum phosphate level is below normal.
Excessive replacement can lead to hypocalcemia.
A serum deficit of about 1 mmol per L of magnesium usually exists. Severe magnesium defi‐
ciency may lead to cardiac dysrhythmias. Magnesium level should be monitored, especially
in patients who receive diuretics and low levels should be corrected in order to avoid this
and other complications of hypomagnesaemia.
In summary, acute myocardial infarction may precipitate diabetic ketoacidosis. Heart failure
following infarction reduces patients’ capacity for volume resuscitation, so clinical features
of hyperglycemic hyperosmolar state and diabetic ketoacidosis may overlap and are ob‐
served simultaneously. Additional risk factors for development of hyperosmolarity include
the presence of congestive heart failure, impaired thirst, limited access to water, older age,
and poor kidney function.
When acidosis is severe, i.e. pH is less than 7.2, the H+ ions have a direct cardiac depres‐
sant  action.  Another  consequence  of  tissue  hypoperfusion resulting both from impaired
myocardial output and increased osmolality as well as counter-regulatory hormone meta‐
bolic  effects  is  increased lactate  production.  Increased lactate  production may aggravate
existing acidosis.
Diabetic acidosis itself may be the precipitating event for the occurrence of a true myocar‐
dial necrosis. Also, the ECG changes in hyperkalemia in DKA can mimic acute anteroseptal
myocardial infarction. Moreover, a bio-marker elevation was also noted, without further
evidence of a true myocardial infarction. Knowing that “silent” myocardial infarction occurs
with higher incidence among diabetics, the differential diagnosis between myocardial ne‐
crosis and hypokalemic disturbances may be difficult.
Since volume repletion must be done cautiously and gradually, its therapeutic reach in dia‐
betic ketoacidosis is limited. Intravenous insulin remains the keystone in treatment of dia‐
betics with AMI, yet their recovery from ketoacidosis may be prolonged. Potassium levels
must be monitored continuously and corrected as need occurs. Phosphate replacement is
needed occasionally. Bicarbonate therapy is not recommended unless pH falls to critically
low levels (<7.0).
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2. Diabetic ketoacidosis and cerebrovascular accidents
Although cerebrovascular accidents represent a significant and well-known precipitating
factor for DKA, the literature data on precise mechanisms, distinctive features or manage‐
ment guidelines for patients are quite few or missing. The prevalence of stroke as the precip‐
itating factor for DKA was 0% in some studies [40] to as much as 7% in others [24].
Considering the data from the recent study in USA, most of the DKA patients (e.g. 80%)
were in the age 18-65 years, with only 18% younger than 18; even 24% of all patients with
DKA were in the age 45-65 years [32] Based on these data, it seems that the prevalence of
DKA in patients with stroke may be underestimated and its importance under-appreciated
in many cases.
Cerebrovascular accidents lead to increased release of counter-regulatory hormones (cate‐
cholamines, cortisol) which lead to hyperglycemia. Hyperglycemia develops as a result of
three processes: increased gluconeogenesis, accelerated glycogenolysis, and impaired glu‐
cose utilization by peripheral tissues. Also these hormones increase the release of free fatty
acids from peripheral tissues and their utilization as the energy source in hepatic and mus‐
cle mitochondria (beta-oxidation) with the increased ketone production as the direct conse‐
quence. This sequence is identical to the one seen in acute myocardial infarction [32], [19].
There is a significant overlapping of the symptoms in stroke and DKA (table 2). One can as‐
sume that an interference of symptoms of the two conditions during the clinical examination
may be confusing and their interpretation difficult particularly in elder and less communica‐
tive patients.
DKA STROKE COMMENTS
Excessive thirst or drinking lots of fluid Inability to swallow
Frequent urination Incontinence Frequent urination and
incontinence may be difficult to
differentiate in a somnolent/
comatose patient
General weakness General weakness, a feeling of
weakness in one arm / leg
Nausea and vomiting Nausea and vomiting
Loss of appetite Loss of appetite Loss of appetite in DKA results
from predominantly catabolic
pattern of metabolism, nausea
and confusion
Confusion, somnolence, stupor, comma Confusion, somnolence, stupor,
comma
Mental status changes can be
seen with mild-to-moderate
DKA; more severe deterioration





Shortness of breath,increased rate of
breathing -Kusmaul’s type
Increased or decreased breathing
frequency, abnormal breathing
patterns, Cheyne-Stokes type
Breathing patterns may be
similar and interchangeably
assigned to either of the
diseases stroke the clinical
examination
A generally ill appearance A generally ill appearance
Dry skin Skin may be dry, or moisture A dehydration may occur in
case of not having access to
water or fluids, or intensive use
of osmotic diuretics
Dry mouth, Often dry mouth
Increased heart rate, Increased heart rate
Low blood pressure Mainly high blood pressure,
sometimes low
A distinctive fruity odor on the breath,
fruity-scented breath
Different kinds of breath odor not
uncommon
Fruity scented breath may be
hardly recognizable. Moreover,
the odor appearing after
ingestion of various sweet and
fruits may imitate the
characteristic odor of DKA
High blood sugar level High sugar level in diabetics Due to the effect of counter-
regulatory hormones
High ketone level in serum and urine Moderately high ketone level in urine
in diabetics, alcohol abuse, starvation
Low (<7.3) plasma pH Plasma pH usually normal
Low serum (<15 mmol/l) bicarbonate Serum bicarbonate usually normal
Increased ( >/12) anion gap Anion gap usually  >/12
Table 2. Symptoms and signs in diabetic ketoacidosis and stroke: the overlapping features
Blood glucose levels are high in the majority of diabetic patients suffering stroke. Moreover,
pH, bicarbonate and anion gap are not routinely monitored in all diabetic patients suffering
stroke, at least not in secondary level health institutions worldwide. In conclusion, some of
the DKA cases in patients with stroke may easily be overlooked.
Furthermore, there is striking lack of literature data concerning management of adult dia‐
betic patients with stroke. Although there are clear concerns about the volume overload, in‐
tensive use of osmotic and Henley’s loop diuretics and the need for careful volume and
monitoring in patients suffering cerebrovascular accident and DKA no clear guidelines were
produced for intensive care units and intensive care neurologic units.
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Some of the management guidelines may be defined here:
1. It is important that patients with stroke complicated by DKA avoid dehydration since
both DKA and stroke correlate with the pro-thrombotic state and dehydration poten‐
tates a tendency toward intravascular thromboembolism. Since the use of osmotic and
sometimes also other kinds of diuretics is inevitable in patients with stroke a careful hy‐
dration is recommended in order to avoid further thrombotic complications.
2. Fluid resuscitation must be performed carefully, in small aliquots, and with constant
monitoring of blood pressure, hematocrit and plasma sodium; novel minimal invasive
procedures [39] should have advantages over central venous catheter since CVP itself
was reported to be a risk factor for cerebrovascular thromboembolism [33]. Excessive
use of diuretics may precipitate pro-thrombotic state.
3. Infused insulin is the principle therapeutic tool for fighting DKA in patients with cere‐
brovascular accidents. Since fluid resuscitation must be restricted, DKA itself is expect‐
ed to have more prolonged clinical course. This may be of importance, since DKA itself
may be a precipitating factor for stroke (see later)
4. Serum potassium must be carefully monitored in all cardiovascular patients with DKA
(see earlier). Hyper or hypokalemia should be promptly corrected; thus said, insulin-in‐
duced intracellular shift of potassium must be taken in account when evaluating potas‐
sium levels or performing potassium substitution
5. Bicarbonate therapy is not recommended except in extreme acidosis.
Not only does stroke precipitate DKA, but the vice-versa is also true [20]: diabetic ketoacido‐
sis itself was reported as a risk factor for the occurrence of stroke in children and youth. The
risk of acute ischemic or hemorrhagic stroke during the acute DKA episode is perhaps un‐
der-appreciated.
Systemic inflammation is present in DKA, with resultant vascular endothelial perturbation
that may result in coagulopathy and increased hemorrhagic risk. Hyperglycemia and acido‐
sis may contribute to oxidative injury [25], as well as ischemic injury [34]. Thrombotic risk
during DKA is also elevated by abnormalities in coagulation factors, platelet activation,
blood volume and flow, and vascular reactivity.
Recent data demonstrate that DKA is associated with reduced cerebral blood flow and with
brain cell swelling [23]. These data suggest that cerebral injury resulting from DKA may be
similar to hypoxic/ischemic brain injury. A cerebral hypo-perfusion occurs in untreated
DKA. [23] In analogy with ischemia/reperfusion injury, DKA could be associated with meta‐
bolic abnormalities similar to those of hypoxic/ischemic brain injury and that these abnor‐
malities would worsen during initial DKA treatment as normal cerebral perfusion is
reestablished [15, 4].
Although a small percentage of children have clinically apparent cerebral injury at presenta‐
tion of DKA prior to treatment, neurological decline during DKA treatment is more com‐
mon [16]. During initial DKA treatment with insulin and intravenous saline, key aspects of
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the cerebral metabolic state worsen. After initiation of DKA therapy, abnormalities in Pro‐
tein C, Protein S, plasma homo-cysteine, and von Willebrand Factor (vWF) were demon‐
strated [11, 9]. While protein C levels normalize with treatment, free protein S, the active
anticoagulant of protein S, is reduced and does not return to baseline with treatment.
Arterial ischemic stroke [47], cerebral venous thrombosis [29], and hemorrhagic stroke [36]
were noted in children following DKA. DKA-associated cerebral edema may also predis‐
pose to ischemic injury and hemorrhage, though cases of stroke without concomitant cere‐
bral edema have been identified [49]. As stroke itself may cause cerebral edema, it becomes
difficult to ascertain whether cerebral edema in DKA is the cause or an effect of acute cere‐
bral infarction. A sub-arachnoid or intra-ventricular hemorrhage may occur without cere‐
bral edema as was demonstrated using on CT scanning. Clinically, a transcranial Doppler
ultrasound in children with DKA demonstrated significant vascular dysregulation with vas‐
odilation, decreased cerebral blood flow velocity, and loss of normal cerebral blood flow
regulation that only normalized after treatment. Another group of researchers found normal
to increased cerebral blood flow with impaired cerebral auto-regulation during episodes of
DKA not associated with overt CE in 6 children [20].
Treatment with bumetanide, [27] an inhibitor of Na-K-2Cl Co-transport, resulted in im‐
provements in metabolic measures during untreated DKA and amelioration of the declines
in metabolic measures during initial DKA treatment.
It is clear that at least some of these mechanisms may be operative in adult DKA. Abnormal‐
ities in coagulation during DKA or its treatment have been also noted in adults. Indeed, an
endothelial injury, platelet activation, relative hypo-fibrinolysis, and activation of the coagu‐
lation system [20] even in the absence of clinical signs of thrombosis were all demonstrated
in patients with DKA. However, the up-regulation was not to a degree expected for the in‐
crease in coagulation activity (thrombin-antithrombin III complex and prothrombin frag‐
ment 1 + 2 levels) at DKA presentation.
In summary, cerebrovascular accidents represent a significant and well-known precipitating
factor for DKA. It seems that the prevalence of DKA in patients with stroke may be underes‐
timated and its importance under-appreciated in many cases.
It is important that patients with stroke complicated by DKA avoid dehydration since both
DKA and stroke correlate with the pro-thrombotic state and dehydration potentates a ten‐
dency toward intravascular thromboembolism. Unfortunately, like in acute myocardial in‐
farction, the volume replenishment capacity in patients with stroke is often limited.
Intravenous insulin and monitoring and correction of possible electrolyte imbalances are the
mainstay of the treatment.
Not only does stroke precipitate DKA, but the vice-versa is also true: diabetic ketoacidosis
itself was reported to be a risk factor for the occurrence of stroke in children and youth. A
cerebral hypo-perfusion occurs in untreated DKA and may lead to cerebral injury. Arterial
ischemic stroke, cerebral venous thrombosis and hemorrhagic stroke were noted following
DKA episodes.
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Treatment with bumetanide, an inhibitor of Na-K-2Cl co-transport, resulted in improve‐
ments in metabolic measures during untreated DKA and prevented cerebral metabolic ag‐
gravation during initial DKA treatment.
3. Diabetic ketoacidosis and renal failure
Renal failure occurs with increased frequency in patients with diabetes. Fortunately, the co‐
incidence of type 1 diabetes with DKA and acute renal failure is uncommon. Volume over‐
load and hyperkalemia may complicate the condition. It has been reported that DKA in
patients with acute renal failure may be sometimes associated with respiratory distress syn‐
drome [17].
3.1. Diabetic ketoacidosis and acute renal failure
Although acute renal failure (ARF) rarely develops in patients with diabetic ketoacidosis
(DKA), these serious complications can be life threatening in critically ill patients [43]. The
estimated mortality with combined DKA and ARF still reaches around 50%. ARF pre-renal
failure may occur as a result of the severe fluid depletion associated with diabetic ketoacido‐
sis; underlying diabetic nephropathy as well as hypotension, sepsis, renal artery occlusion,
serious urinary infections complicated by papillary necrosis and exposure to nephrotoxic
agents. Of the latter, a certain antibiotics and radio-contrast agents, but also angiotensin con‐
verting enzyme inhibitors were mentioned. [51]. The increased incidence of cardiovascular
disease may also lead to renal impairment.
The long-lasting ketoacidosis in combination with infused insulin can lead to severe hypo‐
phosphatemia. Patients with uncontrolled diabetes may already be predisposed to hypo‐
phosphatemia due to osmotic dieresis and often decreased muscle mass; however, the
majority of the imbalance results from phosphate shift from extracellular to intracellular
space[30]. In the presence of metabolic acidosis, proximal tubular reabsorption of phosphate
is inhibited and their urinary excretion is initially increased, thereby critically reducing the
overall level of the extracellular phosphate [10].
Hypophosphatemia, in turn, further contributes to the deepening of the metabolic acidosis.
Acidosis cannot be compensated by renal production of ammonia, because later in the
course of diabetic ketoacidosis, with a reduction in the total amount of phosphate in the
body, a reduction in urinary excretion of phosphate ensues. Prolonged metabolic acidosis
accompanied by hypophosphatemia may be the cause of transient rhabdomyolysis. Acidosis
and rhabdomyolysis lead to renal injury. In addition, prolonged hypophosphataemia can
lead to cardiomyopathy due to decreased concentration of intracellular adenosine - triphos‐
phate and 2.3diphosphoglycerate (DPG). [35]. It is, therefore important to detect changes in
serum phosphate levels of order in early to prevent these complications.
Acute hypophosphatemia may be associated with respiratory problems, confusion, irritabili‐
ty, seizures, ataxia or coma, metabolic acidosis due to reduced phosphate reabsorption.
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However, even the severe symptoms may be hardly recognizable for they can mimic those
of the underlying disease – e.g. DKA itself. Hipophosphatemia may be the cause of rhabdo‐
myolysis, which (though not often) can lead to occurrence of cardiomyopathy and acute re‐
nal failure.
Even after initiation of phosphate replacement, serum phosphate levels are often difficult to
normalize, and a severe metabolic acidosis can last despite insulin-induced normalization of
blood glucose.
In cases of severe acidosis, phosphate replacement is of paramount importance [31]. Howev‐
er, after initial-phase phosphate replacement, the re-institution of acid-base balance phos‐
phate re-shifts from intra- to extracellular space; this can lead to the hyperphosphataemia
later in the course of treatment [13]. Therefore, serum phosphate levels should be monitored
continuously. With the occurrence of acute renal failure, indications for haemodialysis in‐
clude oliguria, persistent metabolic acidosis resistant to standard therapy, fluid overload
and hypertension. Early initiation of haemodialysis is not only effective against the direct
consequences of acute renal failure - uremia and hypervolemia – but also contribute to rapid
correction of metabolic acidosis and hypophosphatemia [28]. Indeed, the existing hypophos‐
phataemia is easily corrected once a normal acid-base balance is established by haemodialy‐
sis. Prompt institution of dialysis is important as the diabetic patient may tolerate uraemia
less well. Uncontrolled ketosis may worsen hyperkaliemia and metabolic acidosis. Insulin
requirements may be increased due to insulin resistance, or decreased due to impaired
clearance of circulating insulin [38, 56].
The vast majority of patients require intermittent haemodialysis. Patients with cardiac dys‐
function or autonomic neuropathy tend to develop hypotension during treatment. Also, an‐
ticoagulation with heparin may increase the risk of hemorrhage from proliferative
retinopathy, therefore prostacyclin may be a safer alternative [52]. Peritoneal dialysis may
be complicated by peritonitis and chest infections. Also, haemodialysis allows greater fluid
removal and remove restrictions for administration of drugs and nutrition [56].
3.2. Diabetic ketoacidosis and chronic renal failure
Despite the strong prevalence of compromised immune status, constant state of protein mal‐
nutrition, frequent vascular accessing with a predisposition to significant infections, in‐
creased incidence of cardiovascular diseases, the occurrence of DKA in patients with chronic
renal failure is quite rare. [41, 3]. Kidneys play a major role in insulin breakdown [38]; ad‐
vanced chronic renal failure is associated with both insulin resistance and decreased insulin
degradation. The latter may lead to a marked decrease in insulin requirement. Therefore,
many patients see an improvement in glycemic control when they progress to haemodialy‐
sis. Furthermore, in hyperglycemic dialysis-dependent patients volume contraction due to
osmotic diuresis is not encountered. Since glycosuria and osmotic diuresis account for most
of the fluid and electrolyte losses seen in DKA, anuric patients may be somewhat protected
from dehydration. However they may still be prone to development of hyperkalemia and
metabolic acidosis [37]. In persistent and long-lasting DKA, a substantial volume loss can
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still occur due to a prolonged decrease in oral intake or increased insensible water losses re‐
lated to tachypnea and fever.
The uremic environment can affect methods used to assess glycemic control. Changes in di‐
etary intake and exercise (ie, reduced intake due to anorexia prior to starting dialysis) can
also affect the response to administered insulin). Renal inability to reabsorb/regenerate bi‐
carbonate and excrete hydrogen ions may lead to metabolic acidosis even in the absence of
DKA; in addition, patients often suffer from anorexia, nausea, vomiting, infections, and
even acute coronary events predisposing them to catabolic pattern of metabolism. In pa‐
tients treated with peritoneal dialysis, glucose contained in peritoneal dialysate will tend to
increase the need for hypoglycemic therapy.
Therefore, the treatment of oliguric patient certainly differs from the wide accepted DKA
treatment guidelines. [8]. First of all, end-stage-renal-disease patients with DKA may be less
likely volume depleted; in most cases the extracellular volume is expanded from its baseline
secondary to hyperglycemia. The volume expansion may cause dyspnea, nausea, vomiting,
seizures and coma [54]. In oliguric patient, fluid hydration in amounts usually administered
in the DKA treatment may precipitate severe pulmonary edema. Therefore, the need for flu‐
id resuscitation in these patients must be justified clinically or by laboratory testing and po‐
tential volume resuscitation should be performed carefully, using central venous access for
continuous monitoring. [2]. When volume overload is apparent, immediate haemodialysis is
the therapy of choice.
Metabolic control can be difficult to achieve. Insulin is normally metabolized by kidneys and
in chronic renal failure insulin degradation is much slower. Furthermore, insulin is not ex‐
creted either by haemodialysis or peritoneal dialysis. Hyperinsulinemia resulting from ag‐
gressive glucose – lowering therapies may easily lead to severe and prolonged
hypoglycemia. One cannot readily predict insulin requirements in this setting and careful
individualized therapy is essential.
As already emphasized, kidneys in end-stage renal disease are not able to contribute to the
overall acid-base balance. Therefore, DKA in these patients may be both profound and pro‐
longed. In addition, pulmonary dysfunction related to volume overload and sometimes un‐
derlying pulmonary infections can impair respiratory compensation to metabolic acidosis.
Bicarbonate administration is rarely of value in DKA [55] and the associated volume, so‐
dium and osmotic overload may be particularly problematic for anuric patients. In this sit‐
uation, significant metabolic acidosis will only be correctable by haemodialysis [53].
Total body concentration of potassium is unchanged, and patients with DKA and end stage
renal failure frequently have a high serum potassium level. Lack of insulin causes transloca‐
tion of intracellular potassium to the extracellular compartment. Hyperglycemia causes hy‐
pertonicity of extracellular fluids, which also leads to shift of potassium from the cells to the
extracellular compartment. The important potassium – lowering effect of osmotic diuresis is
missing. DKA aggravates hyperkalemia in more than 50% of cases [48]. Even when testing
reveals hypokalemia, total body potassium stores may be high, and these patients are un‐
able to excrete a potassium load. Consequently, hypokalemia must be documented and
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acidosis corrected before potassium supplementation is initiated. All dialysis patients pre‐
senting with significant symptoms should undergo immediate cardiac monitoring. If there is
clinical suspicion or electrocardiographic evidence of hyperkalemia, they should receive im‐
mediate potassium lowering therapies, including emergent haemodialysis. [8].
In a study performed in USA in 2001 [1] the occurrence of diabetic ketoacidosis after renal
transplantation was followed. A female sex, recipients of cadaver kidneys, patients age 33–
44 (vs. >55), more recent year of transplant, and patients receiving tacrolimus vs. cyclospor‐
ine had significantly higher risk of diabetic ketoacidosis. However, the rate of diabetic ke‐
toacidosis decreased more over time in tacrolimus users. Diabetic ketoacidosis was
independently associated with increased mortality.
In summary, acute renal failure rarely develops in patients with diabetic ketoacidosis, but it
can be life-threatening. Insulin requirements may be increased due to insulin resistance, or
decreased due to impaired clearance of circulating insulin.
Patients with uncontrolled diabetes may already be predisposed to hypophosphatemia. In
the presence of metabolic acidosis, proximal tubular reabsorption of phosphate is inhibited,
and the overall level of the extracellular phosphate is further reduced. In cases of severe
acidosis, phosphate replacement is of paramount importance.
Indications for haemodialysis in patients with acute renal failure and DKA include oliguria,
persistent metabolic acidosis resistant to standard therapy, fluid overload and hypertension.
Early initiation of haemodialysis is not only effective against uremia and hypervolemia but
also contribute to rapid correction of metabolic acidosis and hypophosphatemia.
The occurrence of DKA in patients with advanced chronic renal failure is quite rare. Chronic
renal failure is associated both with insulin resistance and decreased insulin degradation.
The latter may lead to a marked decrease in insulin requirement. In patients treated with
peritoneal dialysis, glucose contained in peritoneal dialysate will tend to increase the need
for hypoglycemic therapy.
In oliguric patients, fluid hydration in amounts usually administered in DKA treatment may
precipitate severe pulmonary edema. Sodium and osmotic overload may be particularly
problematic for anuric patients. Pulmonary dysfunction due to frequent pulmonary infec‐
tions can impair ventilatory compensation to metabolic acidosis. Bicarbonate administration
is rarely of value in DKA. In this situation, significant metabolic acidosis will only be cor‐
rectable by haemodialysis.
Most DKA patients on both peritoneal and haemodialysis are hyperkalemic and the potassi‐
um replacement in DKA is usually not necessary.
4. Conclusion
Diabetic ketoacidosis is serious metabolic complication in diabetic patients with acute myo‐
cardial infarction, stroke and renal insufficiency. Conversely, severe diabetic ketoacidosis is
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an important risk factor for acute myocardial infarction, stroke and acute renal failure. The
presence of DKA makes patients’ management difficult and aggravates the outcome.
Acidosis in these patients is usually deeper, prolonged and resistant to therapy. In all of the
three conditions a fluid resuscitation in quantities commonly used in the treatment of DKA
can not be performed. In addition, in many cases there is more or less marked insulin resist‐
ance. In chronic renal insufficiency, on the contrary, intensive insulin therapy usual for the
treatment of ketoacidosis may carry a risk of hyperinsulinemia and prolonged hypoglyce‐
mia. Electrolyte imbalance, especially potassium deficiency or excess can have serious con‐
sequences, especially in patients with myocardial infarction, and special care should be
given to electrolyte monitoring.
Finally, we believe that more attention should be paid to the possible acid-base disorders in
diabetic patients suffering cerebrovascular insults. Clinical assesment in these cases is not
sufficient because the significant overlapping of the signs and symptoms, therefore DKA
symptoms may be attributed to cerebrovascular pathology. The conclusions based on blood
glucose levels would not be appropriate, since glycemia tends to be high in distressed pa‐
tients. Acid-base status should be determined routinely, along with glycemia and HbA1c in
all diabetics affected by stroke in order to prevent misdiagnosis.
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